Antiviral activity of nucleoside analogues against norovirus

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 981-991

  Costantini, Verónica P ^a   Whitaker, Tony ^b   Barclay, Leslie ^a   Lee, David ^a   McBrayer, Tamara R ^b   Schinazi, Raymond F ^c   Vinjé, Jan ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b RFS Pharma LLC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 2' METHYLCYTIDINE; 4 AMINO 1 [ 3 FLUORO 4 HYDROXY 5 (HYDROXYMETHYL) 3 METHYLTETRAHYDROFURAN 2 YL]PYRIMIDIN 2[1H]ONE; 4 AMINO 1 [ 3,4 DIHYDROXY 5 (HYDROXYMETHYL) 3 METHYLTETRAHYDROFURAN 2 YL]PYRIMIDIN 2[1H]ONE; BETA HYDROXYCYTIDINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTIDINE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GASTROENTERITIS; HUMANS; LAMIVUDINE; MICE; NOROVIRUS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; VIRUS REPLICATION;

EID: 84865752606     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2229     Document Type: Article

References (47)

1. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol 2009; 44:1-8.
2. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States - major pathogens. Emerg Infect Dis 2011; 17:7-15.
3. Schorn R, Hohne M, Meerbach A, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis 2010; 51:307-314.
4. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008; 14:1553-1557.
5. Bucardo F, Nordgren J, Carlsson B, et al. Asymptomatic norovirus infections in Nicaraguan children and its association with viral properties and histo-blood group antigens. Pediatr Infect Dis J 2010; 29:934-939.
6. Gallimore CI, Cubitt D, du Plessis N, Gray JJ. Asymptomatic and symptomatic excretion of noroviruses during a hospital outbreak of gastroenteritis. J Clin Microbiol 2004; 42:2271-2274.
7. Ozawa K, Oka T, Takeda N, Hansman GS. Norovirus infections in symptomatic and asymptomatic food handlers in Japan. J Clin Microbiol 2007; 45:3996-4005.
8. Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008; 80:1468-1476.
9. Chan MC, Sung JJ, Lam RK, et al. Fecal viral load and norovirus-associated gastroenteritis. Emerg Infect Dis 2006; 12:1278-1280.
10. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. Laboratory efforts to cultivate noroviruses. J Gen Virol 2004; 85:79-87.
11. Lay MK, Atmar RL, Guix S, et al. Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology 2010; 406:1-11.
12. Wobus CE, Karst SM, Thackray LB, et al. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol 2004; 2:e432.
13. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 2006; 353:463-473.
14. Bull RA, Hyde J, Mackenzie JM, et al. Comparison of the replication properties of murine and human calicivirus RNA-dependent RNA polymerases. Virus Genes 2011; 42:16-27.
15. Daughenbaugh KF, Wobus CE, Hardy ME. VPg of murine norovirus binds translation initiation factors in infected cells. Virol J 2006; 3:33.
16. Sosnovtsev SV, Belliot G, Chang KO, et al. Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. J Virol 2006; 80:7816-7831.
17. Chang KO, George DW. Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J Virol 2007; 81:12111-12118.
18. Bok K, Cavanaugh VJ, Matson DO, et al. Inhibition of norovirus replication by morpholino oligomers targeting the 5?-end of the genome. Virology 2008; 380:328-337.
19. Rocha-Pereira J, Cunha R, Pinto DC, Silva AM, Nascimento MS. (E)-2-styrylchromones as potential anti-norovirus agents. Bioorg Med Chem 2010; 18:4195-4201.
20. Changotra H, Jia Y, Moore TN, et al. Type I and type II interferon inhibit the translation of murine norovirus proteins. J Virol 2009; 83:5683-5692.
21. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361:1776-1785.
22. Thackray LB, Wobus CE, Chachu KA, et al. Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. J Virol 2007; 81:10460-10473.
23. Green KY. Caliciviridae: the noroviruses. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B (Editors). Fields Virology. Vol. II. Philadelphia: Lippincott Williams & Wilkins 2007; pp. 949-979.
24. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 2010; 8:231-241.
25. Lindesmith LC, Donaldson EF, Lobue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
26. De Clercq E. Antiviral drug targets and strategies for emerging viral diseases and bioterrorism threats. In Torrence PF (Editors). Antiviral drug discovery for emerging diseases and bioterrorism threats. Hoboken, NJ: John Wiley & Sons, Inc 2005; pp. 83-113.
27. Payment P, Trudel M. Isolation and identification of viruses: titration of viruses in cell culture by cytopathic effect. In Payment P, Trudel M (Editors). Methods and techniques in virology. New York: Marcel Dekker 1993; pp. 32-33.
28. Prichard MN, Shipman C, Jr. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1996; 1:9-20.
29. Prichard MN, Prichard LE, Shipman C, Jr. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 1993; 37:540-545.
30. Trujillo AA, McCaustland KA, Zheng DP, et al. Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol 2006; 44:1405-1412.
31. Park GW, Barclay L, Macinga D, Charbonneau D, Pettigrew CA, Vinje J. Comparative efficacy of seven hand sanitizers against murine norovirus, feline calicivirus, and GII.4 norovirus. J Food Prot 2010; 73:2232-2238.
32. Gentry J, Vinje J, Lipp EK. A rapid and efficient method for quantitation of genogroups I and II norovirus from oysters and application in other complex environmental samples. J Virol Methods 2009; 156:59-65.
33. SPSS Inc. SPSS Statistics 17. Chicago, IL: SPSS Inc. 2008.
34. Bobeck DR, Schinazi RF, Coats SJ. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 2010; 15:935-950.
35. Clark JL, Hollecker L, Mason JC, et al. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem 2005; 48:5504-5508.
36. Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 2003; 47:244-254.
37. Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49:6614-6620.
38. Benzaria S, Bardiot D, Bouisset T, et al. 2′-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication. Antivir Chem Chemother 2007; 18:225-242.
39. Murakami E, Niu C, Bao H, et al. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro- 2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008; 52:458-464.
40. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53:4115-4126.
41. Zamyatkin DF, Parra F, Alonso JM, et al. Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase. J Biol Chem 2008; 283:7705-7712.
42. Zamyatkin DF, Parra F, Machin A, Grochulski P, Ng KK. Binding of 2′-amino-2′-deoxycytidine-5′-triphosphate to norovirus polymerase induces rearrangement of the active site. J Mol Biol 2009; 390:10-16.
43. Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006; 50:3444-3446.
44. Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J Clin Microbiol 2010; 48:168-177.
45. Belliot G, Sosnovtsev SV, Chang KO, McPhie P, Green KY. Nucleotidylylation of the VPg protein of a human norovirus by its proteinase-polymerase precursor protein. Virology 2008; 374:33-49.
46. Rohayem J, Robel I, Jager K, Scheffler U, Rudolph W. Protein-primed and de novo initiation of RNA synthesis by norovirus 3Dpol. J Virol 2006; 80:7060-7069.
47. Ng KK, Arnold JJ, Cameron CE. Structure-function relationships among RNA-dependent RNA polymerases. Curr Top Microbiol Immunol 2008; 320:137-156.